Welsh government funds GSK's Bexsero; Weber says Takeda turnaround involves vaccines focus;

> The Welsh government has agreed to fund GlaxoSmithKline's ($GSK) meningitis B vaccine Bexsero for every baby in the country at a cost of £7.7 million. Report

> Shortly after becoming Takeda CEO, Christophe Weber said the turnaround there has quickened, with a renewed focus on generics, emerging markets and vaccines. Report

> Two novel Ebola vaccines protected macaques against the strain of the virus responsible for the deadly outbreak with no side effects. Story (reg. req.)

> Samsung Pharmaceutical agreed to manufacture and sell GemVax & KAEL Co.'s pancreatic cancer vaccine Rivavax in South Korea until 2020 for 5 billion won ($4.5 million). Report

> Merck ($MRK) and Advaxis ($ADXS) announced enrollment in a Phase I/II study of prostate cancer vaccine ADXS-PSA. in combination with Merck's Keytruda. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.